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To the Editor: Recently, Williams et al.1 examined the
association between hemoglobin A1c (HbA1c) with fasting
plasma glucose and all-cause mortality. This is the first report
with considerable samples size addressing the glycemic
control in maintenance dialysis patients. Notwithstanding
its relative novelty, some limitations may exist in the analyses
of data and drawing conclusions. It would be interesting to
study other potential determinants of HbA1c, especially since
fasting plasma glucose has poor correlation (r2¼ 0.37). The
authors did not clearly mention the role of other risk factors
known to contribute to mortality in the general population,
such as body mass index, exercise, and smoking habits. Many
deaths in diabetic patients may be related to macrovascular
events,2 hence, it would be reasonable to examine the
association between HbA1c and death due to macrovascular
events such as peripheral and cardio-vascular disease rather
than all-cause mortality. The study did not report the
unadjusted comparison of HbA1c levels between deceased
and surviving patients before reporting multivariate analyses.
The authors used HbA1c 6.5–7% as reference range.
Although the foregoing range is usually used as the reference
in the non-end-stage renal disease diabetic patients, it would
be more appropriate to use receiver operating characteristic
curve to find proper level of HbA1c discriminating survival
and mortality to use in the hazard regression models of
dialysis patients. Authors did not clarify which criteria were
used for the diagnosis of type II diabetes.3,4 Whereas the
authors cast doubt on the value of HbA1c as the life
expectancy of red blood cells is about 60 days in end-stage
renal disease patients, they could have used the same period
of time for analyses. Finally, stratification, stepwise con-
founder adjustments, and checking the important interac-
tions between suspected risk factors need to be examined.
Acknowledging the above limitations does not guarantee the
accuracy of conclusions, even when the analyses are not
conducted properly.
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